Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: In their article about neuroprotection
in Parkinson disease (PD), Drs Schapira and Olanow1 briefly
discussed our phase 2 study of coenzyme Q10 in early PD.2 We believe that in their statement that "activity
of daily living scores improved significantly following introduction of the
drug, raising the possibility that an unanticipated symptomatic effect might
also have confounded interpretation," the authors have overstated the significance
of one item in the results.
Shults CW, Haas R, Oakes D, Kieburtz K, Plumb S, Shoulson I, Beal MF, Juncos J, Nutt J. Measuring the Effects of Therapy in Parkinson Disease. JAMA. 2004;291(20):2430-2431. doi:10.1001/jama.291.20.2430-b